Muir K R, Lima M J, Docherty H M, Docherty K
School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK.
QJM. 2014 Apr;107(4):253-9. doi: 10.1093/qjmed/hcu025. Epub 2014 Jan 29.
Cell therapy in the form of human islet transplantation has been a successful form of treatment for patients with type 1 diabetes for over 10 years, but is significantly limited by lack of suitable donor material. A replenishable supply of insulin-producing cells has the potential to address this problem; however to date success has been limited to a few preclinical studies. Two of the most promising strategies include differentiation of embryonic stem cells and induced pluripotent stem cells towards insulin-producing cells and transdifferentiation of acinar or other closely related cell types towards β-cells. Here, we discuss recent progress and challenges that need to be overcome in taking cell therapy to the clinic.
十多年来,人胰岛移植形式的细胞疗法一直是1型糖尿病患者成功的治疗方式,但因缺乏合适的供体材料而受到显著限制。可补充供应的产胰岛素细胞有潜力解决这一问题;然而,迄今为止,成功仅限于少数临床前研究。两种最有前景的策略包括将胚胎干细胞和诱导多能干细胞分化为产胰岛素细胞,以及将腺泡或其他密切相关的细胞类型转分化为β细胞。在此,我们讨论了将细胞疗法应用于临床所需克服的最新进展和挑战。